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Abstract
Infection with protozoan parasites of the genus Leishmania causes a vari-
ety of clinical diseases called leishmaniasis, which is transmitted to human 
host by the bite of a sandfly. Here, we present a Taiwanese man with cuta-
neous leishmaniasis after he had traveled to Sri Lanka. A 35-year-old man 
had a painless erythematous nodule with central ulceration on the ventral 
side of the right wrist. The skin lesion developed 3 weeks after he returned 
to Taiwan from Sri Lanka to rescue tsunami sufferers. Excisional biopsy 
revealed dense and diffuse infiltration of histiocytes and lymphocytes through-
out the dermis, and numerous amastigotes were identified in the cytoplasm 
of the histiocytes. Nine months after he was first treated, his skin lesion 
recurred at the same location. Under the diagnosis of cutaneous leishma-
niasis, he underwent a second excision and took 400 mg itraconazole per 
day for 4 months. No further recurrence or internal organ involvement was 
noted. [Tzu Chi Med J 2008;20(2):147–149]
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1. Introduction
Leishmaniasis is caused by the protozoan Leishmania.
The protozoan is transmitted to mammals, including 
humans, by the saliva of sandfly. It causes several di-
verse clinical diseases, including disseminated vis-
ceral infection (kala azar), cutaneous skin lesion, and 
mucosa leishmaniasis. Cutaneous leishmaniasis (CL) 
is the most common clinical type [1]. Taiwan is not an 
endemic area for leishmaniasis, but many Taiwanese 
travel throughout the world. Physicians should be aware 
of the possibility of contracting CL in travelers who 
have been to endemic areas. We herein present CL in 
a Taiwanese man who had returned from Sri Lanka.
2. Case report
A 35-year-old man volunteered to rescue sufferers in 
Sri Lanka after the tsunami in South Asia in December 
2004. An erythematous papule appeared on the ven-
tral side of his right wrist 3 weeks after he returned to 
Taiwan. Neither pain nor itching was noted. Gradually, 
it became an erythematous nodule with a central ul-
ceration (Fig. 1). The nodule was treated with liquid 
nitrogen with poor response at a clinic. He was then 
referred to the Department of Dermatology at the 
Buddhist Tzu Chi General Hospital. Physical exami-
nation did not reveal any systemic symptoms or signs 
and the skin lesion was totally excised. Pathologic 
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examination revealed dense and diffuse infiltrate of 
histiocytes and lymphocyte in the dermis (Fig. 2A). 
On high magnification, the cytoplasma of the histio-
cytes were found to be filled with numerous bluish to 
grayish colored oval amastigotes (Fig. 2B). The diag-
nosis was CL. Because of complete skin recovery, he 
was lost to follow-up. However, 9 months after the 
initial surgery, an erythematous nodule recurred at the 
same location. It progressively enlarged with a central 
ulceration that produced a volcano-shaped lesion. 
He visited us and received a second excisional biopsy, 
which revealed a similar lobular granulomatous inflam-
matory pattern as that of the first biopsy, but with fewer 
amastigotes in the histiocytic cytoplasm. He received 
400 mg itraconazole per day for 4 months after the 
second excision. No local recurrence or internal organ 
involvement was noted thereafter.
3. Discussion
The World Health Organization has estimated the 
prevalence of CL to be 12 million cases per year. CL 
is classified into two different clinical syndromes: New 
World, when it is acquired in the Americas, which 
is infected by L. mexicana complex (L. mexicana 
mexicana, L. mexicana amazonensis, L. mexicana 
venezuelensis); and Old World, when it is acquired in 
Asia, Africa, the Middle East, or Europe, which is in-
fected by L. major, L. tropica, or L. aethiopica [2,3]. 
Both the Old World and New World forms of CL present 
as a spectrum of diseases ranging from single, chronic 
ulcerative lesions (oriental sores) as in our case, to 
disseminated nodular lesions (diffuse CL). The typi-
cal lesion appears as an erythematous papule at the 
site of inoculation which increases in size and ulcer-
ates. The lesions are round with raised borders and 
appear 2–8 weeks after the patient has been bitten 
by an infected sandfly. Outbreaks of CL may occur in 
war-torn countries or in areas after disasters such as 
the tsunami in the affected regions of Sri Lanka. It is 
not considered to be endemic in Taiwan and physi-
cians in industrialized countries tend to have little 
experience in this type of diagnosis.
The first autochthonous case of CL in Sri Lanka was 
reported in 1992 [4]. The case incidence has increased 
and more than 600 cases of CL were reported in the 
past 4 years [5]. The pathogen of CL in Sri Lanka is
Teishmania donovani which is usually associated with 
visceral leishmaniasis in all Asian and Eastern coun-
tries [6,7]. This may require epidemiologic study to 
identify genetically susceptible patients.
Leishmanial infections are transmitted via the bite 
of infected female sandflies. The parasite lives as an 
extracellular, flagellated promastigote in the gut of the 
insect. After multiplication and differentiation in the 
Fig. 1 — An erythematous nodule with elevated borders 
and central ulceration on the ventral side of the wrist.
A B
Fig. 2 — (A) There are lobular granulomas with infiltration of lymphocytes, macrophages and epithelioid cells throughout 
the dermis; the margin is free (hematoxylin & eosin, 12.5´). (B) Numerous bluish, round to oval shaped amastigotes 
can be identified in the parasitized macrophages (arrows) (hematoxylin & eosin, 1000´).
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sandfly gut, in approximately 1 week, the infectious 
promastigotes migrate to the proboscis. Following in-
oculation into the skin of a mammalian host, macro-
phages engulf promastigotes into the lysosomes and 
the parasites are transformed to obligate intracellular 
life, amastigotes. Free amastigotes are released from 
the infected macrophages and infect dendritic cells. 
Interleukin-12 is released from infected dendritic cells 
and the infected hosts generate antigen-specific T 
cell-dependent immunity, the interferon-γ-producing 
Th1 cells [8]. An important characteristic of Leishmania 
infection is the presence of persistent parasites fol-
lowing resolution of the infection. It appears that these 
parasites are maintained long-term at a very low level 
by the immune response. As infection with Leishmania 
induces a strong cell-mediated immune response, it 
is unclear why the parasites are not completely elim-
inated. Recent studies indicated that one contributing 
factor may be the generation of regulatory T cells dur-
ing the infection, which limit the immune response 
sufficiently to maintain persistent parasites. These 
regulatory T cells function in part by the production 
of interleukin-10 [9,10].
The clinical and histologic appearance of CL skin 
lesions is related to an interaction between the host’s 
immune response and the virulence factors of the 
different Leishmania species. The indication for sys-
temic treatment is the presence of mucosal lesions, 
lymph node metastasis or lesions unresponsive to 
local treatment [11]. The therapeutic cornerstone is 
pentavalent antimonials (Pentostam, Glaxo-Wellcome, 
Research Triangle Park, NC, USA) and meglumine an-
timoniate (Glucantime, Rhone-Poulenc, Paris, France), 
which remain the mainstay of therapy for most forms 
of leishmaniasis. However, those drugs are not avail-
able in Taiwan. Other major treatments include phys-
ical modalities (heat, cryosurgery), local or intralesional 
injections, various anti-infective agents (dapsone, met-
ronidazole, trimethoprim-sulfamethoxazole), amphoter-
icin B, pentamidine, allopurinol, azoles, immunotherapy 
(i.e. interferon-γ), and a variety of agents [12]. In our 
patient, CL presented as a local recurrent ulcerative 
nodule. He had tried cryotherapy first with no effect, 
then received surgical excision. Although recurrent, 
the amount of amastigote in pathology was reduced. 
After the second excision, he took itraconazole as 
combination therapy. Until this writing, no local recur-
rence or remote infection has been noted.
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